# Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

> **NCT07370506** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Tanta University** · enrollment: 36 (estimated)

## Conditions studied

- Breast Cancer
- Doxorubicin Induced Cardiomyopathy

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Doxorubicin (DOX)

## Key facts

- **NCT ID:** NCT07370506
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370506, "Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07370506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*